Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$9.46
-0.52-5.21%
At close: -
$9.46
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Bicara Therapeutics Analyst Ratings and Price Targets | NASDAQ:BCAX | Benzinga
Bicara Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Bicara Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
HC Wainwright & Co.
Cantor Fitzgerald
Wedbush
Stifel
1calculated from analyst ratings
Analyst Ratings for Bicara Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/23/2025 | Buy Now | — | Wells Fargo | Eva Fortea Verdejo32% | $8 → $8 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 05/16/2025 | Buy Now | — | HC Wainwright & Co. | Robert Burns43% | $44 → $41 | Maintains | Buy | Get Alert |
| 04/17/2025 | Buy Now | — | Wells Fargo | Eva Fortea Verdejo32% | → $8 | Initiates | → Underweight | Get Alert |
| 04/07/2025 | Buy Now | — | HC Wainwright & Co. | Robert Burns43% | $45 → $44 | Maintains | Buy | Get Alert |
| 03/13/2025 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt32% | $13.01 → $13.01 | Reiterates | Overweight → Overweight | Get Alert |
| 02/12/2025 | Buy Now | — | Wedbush | David Nierengarten60% | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 02/06/2025 | Buy Now | — | Wedbush | David Nierengarten60% | → $31 | Initiates | → Outperform | Get Alert |
| 01/27/2025 | Buy Now | — | HC Wainwright & Co. | Robert Burns43% | $42 → $45 | Maintains | Buy | Get Alert |
| 12/06/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns43% | → $42 | Initiates | → Buy | Get Alert |
| 10/08/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt32% | — | Initiates | → Overweight | Get Alert |
| 10/08/2024 | Buy Now | — | Stifel | Stephen Willey48% | → $47 | Initiates | → Buy | Get Alert |
| 10/08/2024 | Buy Now | — | Morgan Stanley | Judah Frommer65% | → $35 | Initiates | → Overweight | Get Alert |
| 10/08/2024 | Buy Now | — | TD Cowen | Tyler Van Buren45% | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Bicara Therapeutics (BCAX) stock?
The latest price target for Bicara Therapeutics (NASDAQ:BCAX) was reported by Wells Fargo on May 23, 2025. The analyst firm set a price target for $8.00 expecting BCAX to fall to within 12 months (a possible -15.43% downside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bicara Therapeutics (BCAX)?
The latest analyst rating for Bicara Therapeutics (NASDAQ:BCAX) was provided by Wells Fargo, and Bicara Therapeutics upgraded their equal-weight rating.
When was the last upgrade for Bicara Therapeutics (BCAX)?
The last upgrade for Bicara Therapeutics Inc happened on May 23, 2025 when Wells Fargo raised their price target to $8. Wells Fargo previously had an underweight for Bicara Therapeutics Inc.
When was the last downgrade for Bicara Therapeutics (BCAX)?
There is no last downgrade for Bicara Therapeutics.
When is the next analyst rating going to be posted or updated for Bicara Therapeutics (BCAX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bicara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bicara Therapeutics was filed on May 23, 2025 so you should expect the next rating to be made available sometime around May 23, 2026.
Is the Analyst Rating Bicara Therapeutics (BCAX) correct?
While ratings are subjective and will change, the latest Bicara Therapeutics (BCAX) rating was a upgraded with a price target of $8.00 to $8.00. The current price Bicara Therapeutics (BCAX) is trading at is $9.46, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
